Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients

摘要: The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from diagnosed first primary invasive or situ cancer 1996-1997. Vital followed through end 2005 mean follow-up time 8 years. Promoter eight cancer-related genes assessed by Methy- Light. frequencies for HIN1, RASSF1A, DAPK1, GSTP1, CyclinD2, TWIST, CDH1 RARb 62.9, 85.2, 14.1, 27.8, 19.6, 15.3, 5.8 27.6%, respec- tively. Since rates cancers are substantially different, analyses conducted within 670 cases complete data on all genes. Age-adjusted Cox proportional hazards models revealed that TWIST significantly associated higher cancer-specific mortality. Methylation GSTP1 signifi- cantly all-cause To investigate relationship number meth- ylated mortality, we included previously published MethyLight p16 APC status. mortality increased dose-dependent manner increasing methylated (Ptrend 0.002), although confidence intervals wide. Our results suggest methylation, particularly panel genes, has potential to be used as biomarker predicting prognosis cancer.